Evidence map›Paper›PMID 34638945›Full record

ArticleInternational journal of molecular sciences2021

A 4-Gene Signature of CDKN1, FDXR, SESN1 and PCNA Radiation Biomarkers for Prediction of Patient Radiosensitivity.

Orla Howe, Lisa White, Daniel Cullen, Grainne O'Brien, Laura Shields, Jane Bryant, Emma Noone, Shirley Bradshaw, Marie Finn, Mary Dunne and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Orla HoweSchool of Biological & Health Sciences, Technological University Dublin, Grangegorman, D07 XT95 Dublin, Ireland.ORCID 0000-0002-5150-022X
Lisa WhiteSchool of Biological & Health Sciences, Technological University Dublin, Grangegorman, D07 XT95 Dublin, Ireland.
Daniel CullenRadiation & Environmental Science Centre, FOCAS Research Institute, Technological University Dublin, Camden Row, D08 CKP1 Dublin, Ireland.
Grainne O'BrienCentre for Radiation, Chemical and Environmental Hazards, Radiation Effects Department, Public Health England, Oxfordshire OX11 0RQ, UK.
Laura ShieldsDepartment of Medical Physics, Saint Luke's Radiation Oncology Network, D06 HH36 Dublin, Ireland.
Jane BryantRadiation & Environmental Science Centre, FOCAS Research Institute, Technological University Dublin, Camden Row, D08 CKP1 Dublin, Ireland.
Emma NooneClinical Trials Unit, Saint Luke's Radiation Oncology Network at St Luke's Hospital, D06 HH36 Dublin, Ireland.
Shirley BradshawClinical Trials Unit, Saint Luke's Radiation Oncology Network at St Luke's Hospital, D06 HH36 Dublin, Ireland.
Marie FinnClinical Trials Unit, Saint Luke's Radiation Oncology Network at St Luke's Hospital, D06 HH36 Dublin, Ireland.
Mary DunneClinical Trials Unit, Saint Luke's Radiation Oncology Network at St Luke's Hospital, D06 HH36 Dublin, Ireland.
Aoife M ShannonCancer Trials Ireland, D11 KXN4 Dublin, Ireland.
John ArmstrongCancer Trials Ireland, D11 KXN4 Dublin, Ireland.
Brendan McCleanDepartment of Medical Physics, Saint Luke's Radiation Oncology Network, D06 HH36 Dublin, Ireland.
Aidan MeadeRadiation & Environmental Science Centre, FOCAS Research Institute, Technological University Dublin, Camden Row, D08 CKP1 Dublin, Ireland.ORCID 0000-0003-0353-9768
Christophe BadieCentre for Radiation, Chemical and Environmental Hazards, Radiation Effects Department, Public Health England, Oxfordshire OX11 0RQ, UK.ORCID 0000-0003-4572-5008
Fiona M LyngRadiation & Environmental Science Centre, FOCAS Research Institute, Technological University Dublin, Camden Row, D08 CKP1 Dublin, Ireland.ORCID 0000-0002-9876-963X
St. Luke's Hospital · IETechnological University Dublin · IECancer Trials Ireland · IEPublic Health England · GB

Funding

Science Foundation Ireland 11/RFP.1/BMT/3317Seventh Framework Programme 249689
6 · The paper itself

Abstract

The quest for the discovery and validation of radiosensitivity biomarkers is ongoing and while conventional bioassays are well established as biomarkers, molecular advances have unveiled new emerging biomarkers. Herein, we present the validation of a new 4-gene signature panel of CDKN1, FDXR, SESN1 and PCNA previously reported to be radiation-responsive genes, using the conventional G2 chromosomal radiosensitivity assay. Radiation-induced G2 chromosomal radiosensitivity at 0.05 Gy and 0.5 Gy IR is presented for a healthy control (

Indexed as

TranscriptomeAdultAgedAged, 80 and overAndrogen AntagonistsCase-Control StudiesChromosomesCohort StudiesCyclin-Dependent Kinase Inhibitor p21Heat-Shock ProteinsHumansMaleMiddle AgedMitochondrial ProteinsMultiplex Polymerase Chain ReactionOxidoreductases Acting on Sulfur Group DonorsAndrogen AntagonistsCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Heat-Shock ProteinsMitochondrial ProteinsOxidoreductases Acting on Sulfur Group DonorsPCNA protein, humanProliferating Cell Nuclear AntigenSESN1 protein, humanSestrinsbiomarkersgene expressionradiosensitivity

Identifiers

PMID34638945
PMCPMC8508881
OpenAlexW3204901130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.